Skip to main content
TipRanks
Go Ultimate75% OFF

Tatva Chintan Pharma Chem Limited (TATVA) AI Stock Analysis

3 Followers
IN:TATVA

Tatva Chintan Pharma Chem Limited

(NSE:TATVA)

Select Model
Rating:52Neutral
Price Target:INR 1,676.00â–²(2.44% Upside)
Action:reiterated
Date:10/23/26

The overall score is constrained by a very high valuation and weak technical momentum. The company's financial health is a mixed bag: a robust, low-debt balance sheet provides stability, but significant margin compression and persistent negative free cash flow raise concerns about the sustainability of its capital-intensive growth. The stock's poor short-term price performance and expensive P/E ratio are the primary detractors.

Positive Factors
Revenue RecoveryThe FY2026 revenue rebound indicates renewed demand across the company’s specialty-chemical portfolio after a period of contraction. If maintained, improving sales can support better capacity utilization, strengthen customer relationships, and provide a foundation for earnings recovery over the next several quarters.
Negative Factors
Persistently Negative Free Cash FlowNegative free cash flow across most periods means reported earnings have not consistently translated into cash available after investment. Continued cash shortfalls can increase reliance on the balance sheet to fund expansion, constrain capital allocation, and make the recovery less durable until conversion improves.

Tatva Chintan Pharma Chem Limited (TATVA) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%40%50%IN:TATVA+17.82%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 38.45B
Dividend Yield
0.12%
Average Volume (3M)
5,290
Price to Earnings (P/E)
60.9
Beta (1Y)
0.87
Revenue Growth
49.69%
EPS Growth
254.75%
Country
India
Employees
793
Sector
General
Sector Strength
55
Industry
Chemicals - Specialty

Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model

Company Description

Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for zeo...

How the Company Makes Money

Tatva Chintan Pharma Chem Limited primarily makes money by manufacturing and selling specialty chemicals—mainly SDPTCs and QAS (including bromide-based and other quaternary ammonium salts), along with specialty chemicals and electrolyte salts—to cust...

Tatva Chintan Pharma Chem Limited Financial Statement Overview

Summary

Revenue growth of 16.5% and a strong balance sheet with a 0.15 debt-to-equity ratio are positives. However, gross margin contraction to 35.9% and deeply negative free cash flow of -₹841 million due to heavy capex weigh on the score, indicating recovery with significant cash generation risks.

Income Statement

62Positive

Balance Sheet

85Very Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue6.50B5.06B3.83B3.43B4.24B4.34B
Gross Profit2.75B1.82B619.74M1.60B1.91B2.32B
EBITDA1.29B967.07M-875.86M693.88M680.24M1.09B
Net Income629.18M420.54M57.13M303.54M454.87M958.74M
Balance Sheet
Total Assets11.19B10.04B8.36B8.19B7.60B6.58B
Cash, Cash Equivalents and Short-Term Investments152.05M87.91M117.01M456.68M412.16M638.19M
Total Debt1.70B1.20B363.88M142.71M1.70B1.20B
Total Liabilities3.04B2.22B974.25M816.36M2.44B1.85B
Stockholders Equity8.15B7.82B7.39B7.37B5.15B4.73B
Cash Flow
Free Cash Flow0-841.44M-516.01M-304.71M-1.75B-687.79M
Operating Cash Flow0296.30M246.71M980.44M277.83M203.78M
Investing Cash Flow0-1.17B-652.54M-1.21B-1.01B-1.97B
Financing Cash Flow0816.19M165.66M305.19M377.95M2.35B

Tatva Chintan Pharma Chem Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price1636.10

Price Trends

50DMA1727.69Negative
100DMA1642.17Positive
200DMA1421.69Positive

Market Momentum

MACD-24.93Negative
RSI45.35Neutral
STOCH43.96Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Negative. The current price of 1636.10 is below the 20-day moving average (MA) of 1652.47, below the 50-day MA of 1727.69, and above the 200-day MA of 1421.69, indicating a neutral trend. The MACD of -24.93 indicates Negative momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 43.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TATVA.

Tatva Chintan Pharma Chem Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:TATVA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:VINATIORGAIN:VINATIORGA68NeutralINR 121.70B29.52―0.72%10.98%-5.48%
IN:ROSSARIIN:ROSSARI65NeutralINR 23.69B15.52―0.12%19.76%11.74%
IN:ALKYLAMINEIN:ALKYLAMINE61NeutralINR 80.54B32.52―0.64%13.38%35.82%
IN:JUBLINGREAIN:JUBLINGREA61NeutralINR 91.41B25.83―0.87%15.41%21.76%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:TATVAIN:TATVA52NeutralINR 38.27B60.86―0.12%49.69%254.75%
IN:AARTIINDIN:AARTIIND47NeutralINR 165.88B28.02―0.22%39.85%103.71%

* General Sector Average

Performance Comparison

-40%-20%0%20%40%IN:TATVAIN:AARTIINDIN:ALKYLAMINEIN:JUBLINGREAIN:ROSSARIIN:VINATIORGADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:TATVA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:TATVATatva Chintan Pharma Chem Limited1636.10185.4412.78%
IN:AARTIINDAARTI Industries Ltd457.3073.4119.12%
IN:ALKYLAMINEAlkyl Amines Chemicals Limited1574.65-157.23-9.08%
IN:JUBLINGREAJubilant Ingrevia Ltd.573.90-140.88-19.71%
IN:ROSSARIRossari Biotech Ltd427.75-187.25-30.45%
IN:VINATIORGAVinati Organics Limited1173.95-410.95-25.93%

Tatva Chintan Pharma Chem Limited Corporate Events

Tatva Chintan Corrects Key Ratios in Updated Investor Presentation

Oct 19, 2026

Tatva Chintan Pharma Chem Limited operates in the specialty chemicals and pharmaceutical intermediates sector, supplying advanced chemical formulations to domestic and international markets. Listed on both BSE and NSE under the scrip code 543321 and...

Tatva Chintan Plans Analyst Meeting With Motilal Oswal

Oct 16, 2026

Tatva Chintan Pharma Chem Limited has announced that it will participate in a one-to-one virtual meeting with Motilal Oswal Investment Advisors Limited on 26 October 2026, as part of its regular interactions with analysts, financial institutions and...

Tatva Chintan Schedules Earnings Call for Q2 and H1 FY27 Results

Oct 13, 2026

Tatva Chintan Pharma Chem Limited has scheduled an earnings conference call to discuss its financial results for the quarter and half year ended 30 September 2026. The call, hosted by ICICI Securities and featuring Managing Director Chintan Shah and...

Crisil Upgrades Tatva Chintan’s Credit Ratings on Rs.245 Crore Bank Facilities

Sep 8, 2026

Tatva Chintan Pharma Chem Limited has received an upgrade in its credit profile from Crisil Ratings, which raised the company’s long-term rating to Crisil A-/Stable from Crisil BBB+/Stable and its short-term rating to Crisil A2+ from Crisil A2. The r...

Tatva Chintan Schedules Virtual Investor Meeting with Ventura Securities on July 30

Jul 24, 2026

Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one meeting with Ventura Securities Limited on 30 July 2026 as part of its ongoing engagement with analysts, financial institutions, and investors. The company emphasized that only publ...

Tatva Chintan Plans Investor Meeting with Motilal Oswal AMC

Jul 24, 2026

Tatva Chintan Pharma Chem Limited has scheduled a virtual one-to-one meeting with Motilal Oswal Asset Management Company on July 31, 2026, aimed at engaging analysts, financial institutions and investors. The company emphasized that discussions will...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026